全文获取类型
收费全文 | 52571篇 |
免费 | 3271篇 |
国内免费 | 232篇 |
专业分类
耳鼻咽喉 | 571篇 |
儿科学 | 1443篇 |
妇产科学 | 1212篇 |
基础医学 | 7626篇 |
口腔科学 | 2521篇 |
临床医学 | 4318篇 |
内科学 | 12339篇 |
皮肤病学 | 1698篇 |
神经病学 | 4547篇 |
特种医学 | 838篇 |
外科学 | 4627篇 |
综合类 | 252篇 |
一般理论 | 31篇 |
预防医学 | 5799篇 |
眼科学 | 849篇 |
药学 | 4151篇 |
中国医学 | 306篇 |
肿瘤学 | 2946篇 |
出版年
2023年 | 559篇 |
2022年 | 405篇 |
2021年 | 1943篇 |
2020年 | 1190篇 |
2019年 | 1959篇 |
2018年 | 2590篇 |
2017年 | 1599篇 |
2016年 | 1538篇 |
2015年 | 1886篇 |
2014年 | 2290篇 |
2013年 | 2956篇 |
2012年 | 4900篇 |
2011年 | 5136篇 |
2010年 | 2554篇 |
2009年 | 2027篇 |
2008年 | 3624篇 |
2007年 | 3583篇 |
2006年 | 3218篇 |
2005年 | 3000篇 |
2004年 | 2589篇 |
2003年 | 2210篇 |
2002年 | 1976篇 |
2001年 | 296篇 |
2000年 | 253篇 |
1999年 | 242篇 |
1998年 | 157篇 |
1997年 | 137篇 |
1996年 | 102篇 |
1995年 | 104篇 |
1994年 | 97篇 |
1993年 | 65篇 |
1992年 | 110篇 |
1991年 | 87篇 |
1990年 | 66篇 |
1989年 | 64篇 |
1988年 | 62篇 |
1987年 | 49篇 |
1986年 | 53篇 |
1985年 | 49篇 |
1984年 | 39篇 |
1983年 | 35篇 |
1982年 | 32篇 |
1981年 | 18篇 |
1980年 | 32篇 |
1979年 | 23篇 |
1978年 | 16篇 |
1976年 | 15篇 |
1975年 | 18篇 |
1974年 | 22篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Tiago Ribeiro Leal Larissa Chaves Morais de Lima rick Tssio Barbosa Neves Maria Jacinta Arêa Leo Lopes Araújo Arruda Matheus Frana Perazzo Saul Martins Paiva Júnia Maria Serra-Negra Fernanda de Morais Ferreira Ana Flvia Granville-Garcia 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2022,32(1):22-30
2.
3.
Gevert Mayara Vitorino Soares Renata Wambier Letícia Maira Ribeiro Ana Elisa Avais Letícia Simeoni de Souza Juliana Feltrin Chibinski Ana Cláudia Rodrigues 《Clinical oral investigations》2022,26(10):5989-6002
Clinical Oral Investigations - This overview analyzed the quality of the systematic reviews (SRs) available on treatments for molar-incisor hypomineralization (MIH). Six electronic databases were... 相似文献
4.
Francisco José Álvarez García María José Cilleruelo Ortega Javier Álvarez Aldeán María Garcés-Sánchez Nuria García Sánchez Elisa Garrote Llanos Ángel Hernández Merino Antonio Iofrío de Arce Abián Montesdeoca Melián María Luisa Navarro Gómez Jesús Ruiz-Contreras 《Anales de pediatría (Barcelona, Spain : 2003)》2021,94(1):53.e1-53.e10
The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence.The 2 + 1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2 + 1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks.Rotavirus vaccine should be systematic for all infants.Meningococcal B vaccine, with a 2 + 1 schedule, should be included in routine calendar.In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups.Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine.Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders. 相似文献
5.
6.
7.
8.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
9.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
10.